Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

7.025 -0.065 (-0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TransCode Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Unusual volume stocks are being observed in Tuesday's session.
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
These stocks are moving in today's session
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
The market is filled with gapping stocks in Tuesday's session.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
On Friday, there are stocks with unusual volume. Let's take a look.
These stocks have an unusual volume in today's session 
Via Chartmill
Peering Into TransCode Therapeutics's Recent Short Interest
Via Benzinga
Why TransCode Therapeutics (RNAZ) Stock Is Diving
TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse stock split. 
Via Benzinga
Why Transcode Therapeutics (RNAZ) Stock Is Moving
Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's approval of a 1-for-33 reverse stock split. 
Via Benzinga
TransCode Therapeutics Shares Are Surging Today: What's Going On?
TransCode Therapeutics Inc. (NASDAQ: RNAZ) shares are moving higher Friday after the company announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with its lead... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Crude Oil Gains Over 1%, General Mills Shares Fall
Via Benzinga
Exposures Fossil Fuels
Dow Surges 150 Points, US Current Account Deficit Widens In Q3
Via Benzinga
Topics Stocks
Exposures US Equities
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
Split designed to achieve compliance with Nasdaq minimum bid price requirements 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
From TransCode Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
From TransCode Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewal 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
Grant awarded by the National Cancer Institute (NCI) of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024
RNAZ stock results show that TransCode Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
TransCode Therapeutics, Inc. Announces Closing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.